Researchers performed a genetically engineered pig kidney transplant into a brain‑dead human decedent and maintained graft function for 61 days while collecting serial samples for comprehensive physiological and multi‑omics analysis. The team published detailed molecular and cellular maps of the xenograft’s immune interactions in Nature, identifying antibody and T‑cell signatures that drove rejection and showing pharmacologic reversal with approved agents. The work—led by surgeons and immunologists including Robert Montgomery at NYU Grossman—paired histology, single‑cell transcriptomics, and serum profiling to chart progressive immune events in unprecedented temporal resolution. Investigators demonstrated that a combined regimen targeting both humoral and cellular arms could reverse rejection without permanent graft damage. These results provide an operational blueprint for anticipating immune barriers in living recipients and justify near‑term clinical trials with intensified immunomodulation and engineered donor genetics. The dataset also furnishes biomarkers for patient monitoring and targetable pathways for next‑generation donor edits.